Related Experiment Videos

A review of evidence-based beta-blockers in special populations with heart failure

Gregg C Fonarow1

  • 1Ahmanson-UCLA Cardiomyopathy Center, UCLA Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.

Reviews in Cardiovascular Medicine
|July 29, 2008
PubMed

Insights

Beta-blockers effectively treat systolic heart failure (HF), reducing mortality. However, their use in special populations like women, the elderly, African Americans, and those with diabetes or atrial fibrillation needs further investigation for tailored recommendations.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Guidelines recommend bisoprolol, carvedilol, or metoprolol succinate for systolic heart failure (HF).
  • Beta-blockers are proven to reduce mortality in HF based on extensive clinical trial data.
  • Underutilization of beta-blockers in eligible HF patients may stem from uncertainty regarding their use in special populations.

Purpose of the Study:

  • To review clinical trial data on beta-blocker efficacy and safety in special heart failure populations.
  • To identify potential differences in beta-blocker benefits across diverse patient groups.

Main Methods:

  • Analysis of existing randomized, placebo-controlled clinical trials involving over 20,000 heart failure patients.
  • Stratified review of data focusing on subgroups including women, the elderly, African Americans, patients with diabetes, and those with atrial fibrillation.

Main Results:

  • No evidence suggests one recommended beta-blocker is superior to others in women or the elderly with HF.
  • Carvedilol may offer greater benefits in African American patients, and those with diabetes or atrial fibrillation.
  • Further research is required to establish evidence-based recommendations for these special populations.

Conclusions:

  • Current evidence does not support preferential use of specific beta-blockers in women or elderly HF patients.
  • Carvedilol shows potential for enhanced benefit in specific subgroups, warranting further investigation.
  • More data are needed to refine beta-blocker treatment guidelines for diverse heart failure patient populations.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...